Clinical Research Directory

Inclusion Criteria: * Female initial treatment patients aged ≥ 18 years and ≤ 70 years old * ECOG score 0-1 * Clinical T1-2N0 HER2 positive ( HR negative HER2 IHC score of 3+, or 2+and ISH test positive) or triple negative invasive breast cancer * Left ventricular ejection fraction (LVEF) ≥ 50% * 12 lead electrocardiogram: QT interval (QTcF) corrected by Fridericia method for females\<470ms * The functional level of the main organs must meet the following requirements: blood routine: ANC ≥ 1.5 × 109/L# PLT≥90 × 109/L# Hb≥90 g/L#Blood biochemistry: TBIL ≤ 2.5 × ULN# ALT and AST ≤ 2.5 × ULN# BUN and Cr ≤ 1.5 × ULN# * For female subjects who have not undergone menopause or surgical sterilization, during the treatment period and during the study treatment * Agree to abstain or use effective contraceptive methods for at least 2 months after the next administration; .Volunteer to join this study, sign informed consent, have good compliance, and be willing to cooperate with follow-up. Exclusion Criteria: * Inflammatory breast cancer * Metastatic tumor * Previous or concurrent malignant tumors, whose natural history or treatment may interfere with the safety of the research protocol. * Active infections that require systemic treatment * Has used any medication in this study within 14 days prior to enrollment * Major surgery (excluding biopsy) performed within 14 days before enrollment